- Home
- EVER vs PHAT Comparison
EVER vs PHAT Comparison
Compare EVER & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVER | PHAT |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.5M | 894.0M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EVER | PHAT |
|---|---|---|
| Price | $16.79 | $10.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $27.00 | $19.50 |
| AVG Volume (30 Days) | ★ 1.1M | 924.5K |
| Earning Date | 05-25-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 198.86 | 42.72 |
| EPS | ★ 2.63 | N/A |
| Revenue | $163,349,000.00 | ★ $175,110,000.00 |
| Revenue This Year | $14.68 | $83.18 |
| Revenue Next Year | $11.86 | $61.43 |
| P/E Ratio | $6.39 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $13.93 | $2.21 |
| 52 Week High | $30.03 | $18.31 |
Technical Indicators
Market Signals| Indicator | EVER | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 35.31 |
| Support Level | $13.93 | $10.65 |
| Resistance Level | $26.85 | $12.77 |
| Average True Range (ATR) | 0.89 | 0.90 |
| MACD | 0.52 | -0.05 |
| Stochastic Oscillator | 77.05 | 13.61 |
Price Performance
Historical ComparisonAbout EVER EverQuote Inc.
EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.